The Michael Mason prize: early rheumatoid arthritis--the window narrows
Open Access
- 2 December 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (3), 406-410
- https://doi.org/10.1093/rheumatology/kep392
Abstract
RA is a chronic disease in which synovitis drives joint destruction. Immunomodulatory therapy in the established phase of disease limits synovitis, and slows the rate of joint destruction, but is not curative. Increasing evidence suggests that the very early phase of RA, within the first few months after the onset of symptoms, represents a pathologically distinct and temporally transient window during which outcomes can be more effectively modulated by therapy. Furthermore, recent data show that we can accurately predict the development of RA in patients with very early synovitis, using clinical and serological measures. This makes very early targeted treatment a realistic possibility. However, it remains the case that the majority of patients with very early synovitis delay for prolonged periods before seeking medical help. Effective public engagement, to reduce this delay, is the key to translate advances in the fields of pathology, prognostication and therapy into benefit for patients with new onset RA.Keywords
This publication has 41 references indexed in Scilit:
- Predicting the development of RA in patients with early undifferentiated arthritisBest Practice & Research Clinical Rheumatology, 2009
- Patients with suspected rheumatoid arthritis should be referred early to rheumatologyBMJ, 2008
- Treating very early rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2006
- Resolution of inflammation: the beginning programs the endNature Immunology, 2005
- Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritisRheumatology, 2004
- Methotrexate and mortality in patients with rheumatoid arthritis: a prospective studyThe Lancet, 2002
- Treating rheumatoid arthritis early: A window of opportunity?Arthritis & Rheumatism, 2002
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- Interferon-β mediates stromal cell rescue of T cells from apoptosisEuropean Journal of Immunology, 1999
- Inhibition of T cell apoptosis in the rheumatoid synovium.JCI Insight, 1997